<DOC>
	<DOCNO>NCT01653444</DOCNO>
	<brief_summary>The purpose study evaluate safety exploratory efficacy GC1119 ( recombinant human α-galactosidase A ) enzyme replacement therapy Fabry disease patient .</brief_summary>
	<brief_title>Evaluate Safety Exploratory Efficacy GC1119</brief_title>
	<detailed_description />
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>Subjects current diagnosis Fabry 's disease Plasma αgal activity ≤ 1.5mnol/hr/ml mutation αgalactosidase A gene Males ≥ 16 year old Subjects capable perform clinical trial appropriate manner Informed consent form voluntarily sign subject ( legally acceptable representative subject 20 year old ) participation study Agreement contraception study period Serum creatinine &gt; 2.5mg/dl Subjects plan kidney transplantation Subjects undergone kidney transplantation Subjects currently dialysis Subjects clinically significant organic disease ( cardiovascular , hepatic , pulmonary , neurologic , renal disease ) opinion investigator would preclude participation trial Known lifethreatening hypersensitivity ( anaphylactic reaction ) αgalactosidase Treatment another investigational product within 30days administration study drug dose plan treat another investigational product study period Known hypersensitivity ingredient study drug ( include excipients ) Subjects need medication prohibit drug Alcoholism drug addiction</criteria>
	<gender>Male</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>